News & Events

Immune Targeting Systems announces positive Phase 2a data in the at risk elderly population with Flunisyn™, its pan-strain influenza A T-cell vaccine, and two UK Biomedical Catalyst grants for Chronic Hepatitis B and Oncology

Immune Targeting Systems announces positive Phase I data for Flunisyn™, its pan-strain influenza-A T-cell vaccine, and changes to the Company’s senior management team

Carlton Brown steps down as CEO of Immune Targeting Systems Ltd.

ITS announces first patient treated in phase I trial of synthetic universal influenza vaccine

ITS secures £8.65m to fund Synthetic Flue Vaccine development

Immune Targeting Systems confirms industry heavyweight Ken Powell as new Chairman

Immune Targeting Systems completes second tranche of series-A funding bringing total funds raised to more than £5m